Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis

F. Piazza, J. C. DiFrancesco, M. L. Fusco, D. Corti, L. Pirovano, B. Frigeni, L. Mattavelli, S. Andreoni, M. Frigo, C. Ferrarese, G. Tredici, G. Cavaletti

Research output: Contribution to journalArticle

Abstract

Objective and subjects: To examine in vivo levels of BAFF (B-cell activating factor of the tumor necrosis factor family) and APRIL (a proliferation-inducing ligand) in both the cerebrospinal fluid (CSF) and serum of 30 naïve MS patients and 79 subjects affected by acute or chronic inflammatory or non-inflammatory neurological diseases. Design: Case-control study. Results: No difference among groups was evidenced in serum BAFF or APRIL levels. By contrast, CSF levels of BAFF in MS (mean 144.3 pg/ml ± 141.2), although not significantly different from those observed in NIND (164.2 pg/ml ± 92.0), acute peripheral OIND (243.1 pg/ml ± 139.0) or chronic OIND (240.2 pg/ml ± 122.5), were significantly higher in acute central OIND patients (1274.0 pg/ml ± 803.8; p <0.001 vs. all groups). Similarly, CSF APRIL levels in MS (1541.0 pg/ml ± 1071.0), NIND (2629.0 pg/ml ± 1669.0), acute peripheral OIND (2834.0 pg/ml ± 1118.) or chronic OIND (2764.0 pg/ml ± 659.7) were not significantly different, while they were significantly higher in acute central OIND (6218.0 pg/ml ± 3790.0; p <0.001 vs. MS and NIND; and p <0.05 vs. acute peripheral OIND). Conclusions: Our results strongly suggest that further investigation is warranted to elucidate the role of BAFF and APRIL in MS and that serum levels of BAFF and APRIL do not reflect CSF levels.

Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalJournal of Neuroimmunology
Volume220
Issue number1-2
DOIs
Publication statusPublished - Mar 30 2010

Fingerprint

Multiple Sclerosis
Cerebrospinal Fluid
Ligands
Serum
B-Cell Activating Factor
Case-Control Studies
Tumor Necrosis Factor-alpha

Keywords

  • APRIL (a proliferation-inducing ligand)
  • BAFF (B-cell activating factor of the tumor necrosis factor family)
  • Cerebrospinal fluid
  • Multiple sclerosis (MS)

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Piazza, F., DiFrancesco, J. C., Fusco, M. L., Corti, D., Pirovano, L., Frigeni, B., ... Cavaletti, G. (2010). Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. Journal of Neuroimmunology, 220(1-2), 104-107. https://doi.org/10.1016/j.jneuroim.2010.01.011

Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. / Piazza, F.; DiFrancesco, J. C.; Fusco, M. L.; Corti, D.; Pirovano, L.; Frigeni, B.; Mattavelli, L.; Andreoni, S.; Frigo, M.; Ferrarese, C.; Tredici, G.; Cavaletti, G.

In: Journal of Neuroimmunology, Vol. 220, No. 1-2, 30.03.2010, p. 104-107.

Research output: Contribution to journalArticle

Piazza, F, DiFrancesco, JC, Fusco, ML, Corti, D, Pirovano, L, Frigeni, B, Mattavelli, L, Andreoni, S, Frigo, M, Ferrarese, C, Tredici, G & Cavaletti, G 2010, 'Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis', Journal of Neuroimmunology, vol. 220, no. 1-2, pp. 104-107. https://doi.org/10.1016/j.jneuroim.2010.01.011
Piazza F, DiFrancesco JC, Fusco ML, Corti D, Pirovano L, Frigeni B et al. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. Journal of Neuroimmunology. 2010 Mar 30;220(1-2):104-107. https://doi.org/10.1016/j.jneuroim.2010.01.011
Piazza, F. ; DiFrancesco, J. C. ; Fusco, M. L. ; Corti, D. ; Pirovano, L. ; Frigeni, B. ; Mattavelli, L. ; Andreoni, S. ; Frigo, M. ; Ferrarese, C. ; Tredici, G. ; Cavaletti, G. / Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. In: Journal of Neuroimmunology. 2010 ; Vol. 220, No. 1-2. pp. 104-107.
@article{2bbae972a76542b192e0ef8547efed5d,
title = "Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis",
abstract = "Objective and subjects: To examine in vivo levels of BAFF (B-cell activating factor of the tumor necrosis factor family) and APRIL (a proliferation-inducing ligand) in both the cerebrospinal fluid (CSF) and serum of 30 na{\"i}ve MS patients and 79 subjects affected by acute or chronic inflammatory or non-inflammatory neurological diseases. Design: Case-control study. Results: No difference among groups was evidenced in serum BAFF or APRIL levels. By contrast, CSF levels of BAFF in MS (mean 144.3 pg/ml ± 141.2), although not significantly different from those observed in NIND (164.2 pg/ml ± 92.0), acute peripheral OIND (243.1 pg/ml ± 139.0) or chronic OIND (240.2 pg/ml ± 122.5), were significantly higher in acute central OIND patients (1274.0 pg/ml ± 803.8; p <0.001 vs. all groups). Similarly, CSF APRIL levels in MS (1541.0 pg/ml ± 1071.0), NIND (2629.0 pg/ml ± 1669.0), acute peripheral OIND (2834.0 pg/ml ± 1118.) or chronic OIND (2764.0 pg/ml ± 659.7) were not significantly different, while they were significantly higher in acute central OIND (6218.0 pg/ml ± 3790.0; p <0.001 vs. MS and NIND; and p <0.05 vs. acute peripheral OIND). Conclusions: Our results strongly suggest that further investigation is warranted to elucidate the role of BAFF and APRIL in MS and that serum levels of BAFF and APRIL do not reflect CSF levels.",
keywords = "APRIL (a proliferation-inducing ligand), BAFF (B-cell activating factor of the tumor necrosis factor family), Cerebrospinal fluid, Multiple sclerosis (MS)",
author = "F. Piazza and DiFrancesco, {J. C.} and Fusco, {M. L.} and D. Corti and L. Pirovano and B. Frigeni and L. Mattavelli and S. Andreoni and M. Frigo and C. Ferrarese and G. Tredici and G. Cavaletti",
year = "2010",
month = "3",
day = "30",
doi = "10.1016/j.jneuroim.2010.01.011",
language = "English",
volume = "220",
pages = "104--107",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis

AU - Piazza, F.

AU - DiFrancesco, J. C.

AU - Fusco, M. L.

AU - Corti, D.

AU - Pirovano, L.

AU - Frigeni, B.

AU - Mattavelli, L.

AU - Andreoni, S.

AU - Frigo, M.

AU - Ferrarese, C.

AU - Tredici, G.

AU - Cavaletti, G.

PY - 2010/3/30

Y1 - 2010/3/30

N2 - Objective and subjects: To examine in vivo levels of BAFF (B-cell activating factor of the tumor necrosis factor family) and APRIL (a proliferation-inducing ligand) in both the cerebrospinal fluid (CSF) and serum of 30 naïve MS patients and 79 subjects affected by acute or chronic inflammatory or non-inflammatory neurological diseases. Design: Case-control study. Results: No difference among groups was evidenced in serum BAFF or APRIL levels. By contrast, CSF levels of BAFF in MS (mean 144.3 pg/ml ± 141.2), although not significantly different from those observed in NIND (164.2 pg/ml ± 92.0), acute peripheral OIND (243.1 pg/ml ± 139.0) or chronic OIND (240.2 pg/ml ± 122.5), were significantly higher in acute central OIND patients (1274.0 pg/ml ± 803.8; p <0.001 vs. all groups). Similarly, CSF APRIL levels in MS (1541.0 pg/ml ± 1071.0), NIND (2629.0 pg/ml ± 1669.0), acute peripheral OIND (2834.0 pg/ml ± 1118.) or chronic OIND (2764.0 pg/ml ± 659.7) were not significantly different, while they were significantly higher in acute central OIND (6218.0 pg/ml ± 3790.0; p <0.001 vs. MS and NIND; and p <0.05 vs. acute peripheral OIND). Conclusions: Our results strongly suggest that further investigation is warranted to elucidate the role of BAFF and APRIL in MS and that serum levels of BAFF and APRIL do not reflect CSF levels.

AB - Objective and subjects: To examine in vivo levels of BAFF (B-cell activating factor of the tumor necrosis factor family) and APRIL (a proliferation-inducing ligand) in both the cerebrospinal fluid (CSF) and serum of 30 naïve MS patients and 79 subjects affected by acute or chronic inflammatory or non-inflammatory neurological diseases. Design: Case-control study. Results: No difference among groups was evidenced in serum BAFF or APRIL levels. By contrast, CSF levels of BAFF in MS (mean 144.3 pg/ml ± 141.2), although not significantly different from those observed in NIND (164.2 pg/ml ± 92.0), acute peripheral OIND (243.1 pg/ml ± 139.0) or chronic OIND (240.2 pg/ml ± 122.5), were significantly higher in acute central OIND patients (1274.0 pg/ml ± 803.8; p <0.001 vs. all groups). Similarly, CSF APRIL levels in MS (1541.0 pg/ml ± 1071.0), NIND (2629.0 pg/ml ± 1669.0), acute peripheral OIND (2834.0 pg/ml ± 1118.) or chronic OIND (2764.0 pg/ml ± 659.7) were not significantly different, while they were significantly higher in acute central OIND (6218.0 pg/ml ± 3790.0; p <0.001 vs. MS and NIND; and p <0.05 vs. acute peripheral OIND). Conclusions: Our results strongly suggest that further investigation is warranted to elucidate the role of BAFF and APRIL in MS and that serum levels of BAFF and APRIL do not reflect CSF levels.

KW - APRIL (a proliferation-inducing ligand)

KW - BAFF (B-cell activating factor of the tumor necrosis factor family)

KW - Cerebrospinal fluid

KW - Multiple sclerosis (MS)

UR - http://www.scopus.com/inward/record.url?scp=77649185560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649185560&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2010.01.011

DO - 10.1016/j.jneuroim.2010.01.011

M3 - Article

C2 - 20149932

AN - SCOPUS:77649185560

VL - 220

SP - 104

EP - 107

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -